Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

Olga Kulemina, MD, Nadia Siordia, MD, Konstantin Bogdanov, PhD, Julia Alexeeva, MD PhD, Larisa Girshova, MD PhD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD PhD

Blood (2019) 134 (Supplement_1): 5138.

https://doi.org/10.1182/blood-2019-129815

Published: 2019

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

Survival Outcome of Imatinib Mono Therapy in Chronic Phase Chronic Myeloid Leukemia - a Single Center Experience in Belorus

Janna Kozich, MD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD

Blood (2016) 128 (22): 5452.

https://doi.org/10.1182/blood.V128.22.5452.5452

Published: 2016

Journal Articles

Incidence of Elevated Expression of wt1 in Primary Myelofibrosis (pmf) and Postpv-, Postet Myelofibrosis and Its Dynamics during Ruxolitinib Treatmeny

Nadiya Siordiya, Ekaterina Lisina, MD, Pavel Butylin, PhD, Natalia Matuhina, Konstantin Bogdanov, Anna Silutina, Elza Lomaia, MD PhD, Andrey Zaritskiy, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 5498.

https://doi.org/10.1182/blood.V128.22.5498.5498

Published: 2016

Journal Articles

Calreticulin Mutations Variants of ET and PMF Patients Studied in Almazov Medical Research Center Russian Federation

Pavel Butylin, PhD, Natalia Matyuhina, MS, Ekaterina Lisina, MD, Nadia Siordia, MD, Olga Senderova, MD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD

Blood (2016) 128 (22): 5499.

https://doi.org/10.1182/blood.V128.22.5499.5499

Published: 2016

Journal Articles

Quality of Life (QoL) and Clinical Outcomes of Dasatinib Treatment in TKI-Naive and Early Switched from Imatinib Patients with Chronic Myeloid Leukemia in Chronic Phase (CP CML) in a Real World Setting

Tatyana Ionova, PhD, Natalia Bulieva, MD, Olga Vinogradova, MD PhD, Kira Kurbatova, Elza Lomaia, MD PhD, Tatyana Nikitina, MD PhD, Natalia Novitskaya, Anna Rodionova, MD PhD, Elena Usacheva, Marina Chukavina, Marina Shumkova

Blood (2016) 128 (22): 5456.

https://doi.org/10.1182/blood.V128.22.5456.5456

Published: 2016

Journal Articles

Patient-Reported Outcomes in Myelofibrosis Patients Help to Identify Patients' Needs

Tatyana Ionova, PhD, Tatyana Nikitina, MD PhD, Elza Lomaia, MD PhD, Alexandr Myasnikov, MD PhD, Tatyana Pospelova, MD PhD, Andrey Evseev, MD PhD, Taras Gritsenko, MD PhD, Anna Lyamkina, MD PhD, Elena Machulaytene, MD PhD, Elena Usacheva, MD PhD, Anna Rodionova, MD PhD, Kira Kurbatova

Blood (2015) 126 (23): 5198.

https://doi.org/10.1182/blood.V126.23.5198.5198

Published: 2015

Journal Articles

Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities

Tatyana Ionova, PhD, Tatyana Nikitina, MD PhD, Galina Kuchma, MD PhD, Elza Lomaia, MD PhD, Tatyana Shnaider, MD PhD, Elena Usacheva, MD PhD, Kira Kurbatova

Blood (2015) 126 (23): 5147.

https://doi.org/10.1182/blood.V126.23.5147.5147

Published: 2015

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Elza Lomaia, MD PhD, Andrey Zaritskey, MD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Mikhail Fominykh, MD, Ekaterina Ovsyannikova, MD, Natalia Lazorko, MD, Natalia Matyuhina, MS, Pavel Butylin, PhD, Elena Machyulaitene, MD, Evgenia Salamatova, MD, Kudrat Abdulkadyrov, MD PhD

Blood (2015) 126 (23): 4051.

https://doi.org/10.1182/blood.V126.23.4051.4051

Published: 2015

Journal Articles

“FLAG” Regimen Induces Deep, Although Short-Term, Responses in Patients Resistant to Tyrosine Kinases Inhibitors in BP CML.

Ekaterina Romanova, MD, Larisa Girshova, MD, Nadia Siordia, MD, Elena Goriunova, MD, Dmitry Motorin, MD PhD, Elza Lomaia, MD PhD, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 5534.

https://doi.org/10.1182/blood.V124.21.5534.5534

Published: 2014

Journal Articles

Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience

Elza Lomaia, MD, PhD, Ekaterina Romanova, MD, Larisa Girshova, MD, Yulia Alexeeva, MD, PhD, Eugenia Sbityakova, MD, Elena Goriunova, MD, Vladimir Strugov, MD, Natalia Lazorko, MD, Nadia Siordia, MD, Diana Mescheryakova, MD, Tatiana Silina, MD, Dmitry Motorin, MD, PhD, Andrey Zaritskey, MD, PhD

Blood (2013) 122 (21): 5173.

https://doi.org/10.1182/blood.V122.21.5173.5173

Published: 2013

NARROW

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Survival Outcome of Imatinib Mono Therapy in Chronic Phase Chronic Myeloid Leukemia - a Single Center Experience in Belorus

Incidence of Elevated Expression of wt1 in Primary Myelofibrosis (pmf) and Postpv-, Postet Myelofibrosis and Its Dynamics during Ruxolitinib Treatmeny

Calreticulin Mutations Variants of ET and PMF Patients Studied in Almazov Medical Research Center Russian Federation

Quality of Life (QoL) and Clinical Outcomes of Dasatinib Treatment in TKI-Naive and Early Switched from Imatinib Patients with Chronic Myeloid Leukemia in Chronic Phase (CP CML) in a Real World Setting

Patient-Reported Outcomes in Myelofibrosis Patients Help to Identify Patients' Needs

Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

“FLAG” Regimen Induces Deep, Although Short-Term, Responses in Patients Resistant to Tyrosine Kinases Inhibitors in BP CML.

Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only